8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 28, 2011

REVA MEDICAL, INC.
(Exact name of registrant as specified in its charter)

Delaware	000-54192	33-0810505
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5751 Copley Drive, Suite B San Diego, CA 92111	92111
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (858) 966-3000

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On February 28, 2011, representatives of REVA Medical, Inc. (“REVA”) are making a presentation at the Cardiovascular Research Technology “CRT 2011” conference in Washington, DC.  The presentation materials to be delivered at the conference are attached hereto as Exhibit 99.1. A copy of the slides has also been posted under the Investor Relations section of REVA’s website, www.revamedical.com.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including Exhibit 99.1, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This Current Report on Form 8-K and the presentation include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair REVA’s operating performance or developments, include without limitation, expectations with respect to regulatory submissions and approvals, expectations with respect to clinical trials, including enrollment in or completion of clinical trials, expectations with respect to the integrity or capabilities of REVA’s intellectual property position, REVA’s ability to commercialize existing products, REVA’s ability to develop and commercialize new products, and REVA’s estimates regarding capital requirements and financial performance, including profitability. More detailed information about REVA’s risks are disclosed in the “Risk Factors” section contained in REVA’s final prospectus filed pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended, and other periodic reports filed with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Cardiovascular Research Technology “CRT 2011” Conference Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

REVA Medical, Inc.

Date: February 28, 2011

/s/ Katrina Thompson                           
Katrina Thompson
Chief Financial Officer
(principal financial and
accounting officer)

Index to Exhibits

Exhibit No.	Description
99.1	Cardiovascular Research Technology “CRT 2011” Conference Presentation

EX-99.1

Exhibit 99.1

The REVA Tyrosine-Derived Polycarbonate Bioresorbable Scaffold: Long-term Outcomes Using Multimodality Imaging Greg L. Kaluza, MD, PhD, FACC Director of Research, Skirball Center for Cardiovascular Research Cardiovascular Research Foundation New York, NY

Disclosure Statement REVA Medical, Inc. Personal: scientific consultant Institutional: SCCR performs a small volume of contract animal research for REVA and provides image core lab services

Tamai H et al, www.tctmd.com: 3-year QCA outcomes of the PLLA Igaki-Tamai coronary stent Serruys PW et al, Lancet 2009; 373:897-910. 2-year outcomes of the ABSORB trial Clinical studies with bioresorbable PLLA scaffolds suggest late lumen expansion at 2-3 years post implantation It remains unclear what the mechanism of this phenomenon is, and if it is universal to different bioresorbable scaffolds

REVA 1st Gen Bioresorbable Non-Drug Eluting Scaffold Unique Geometry Unique Material Radiopaque Material Slide and Lock Mechanism

Methods Pig (Yucatan miniswine) coronary arteries evaluated (pooled from several studies): 94 REVA 1st Generation ("R100") Bioresorbable Non-Drug Eluting Scaffolds 46 BMS (BSC Express) Evaluated immediately post-implant, 5 days; 3, 6, 12, 18, 24 and 55 months post-treatment In Vivo Multimodality Imaging: Angiography and rotational angiography IVUS OCT RESORB Trial Patients: 3 REVA 1st Generation Bioresorbable Non-Drug Eluting Scaffolds Implant, 4, 12 and 34 months post-treatment

Bioresorbable (No Drug) Bare Metal Post Implant 5 Day 3 Mo 6 Mo 12 Mo 18 Mo 24 Mo 55 Mo Kaluza et al, Am J Cardiol 2009; 104 (Suppl 6A): 165D. Post Implant 5 Day 3 Mo 6 Mo 12 Mo 18 Mo 24 Mo 55 Mo In Animals, IVUS Lumen and Scaffold Area Changes Over Time

Post Implant 180 Days 365 Days 90 Days 30 Days 5 Days Bioresorbable (No Drug) Bare Metal Bioresorbable Scaffold Area Changes Are Evident at 180 Days+ Kaluza et al, Am J Cardiol 2009; 104 (Suppl 6A): 165D.

Remodeling Ratio The remodeling ratio depicts the patency and tubularity of the scaffold- or stent-treated region vs. the adjacent reference vessel segments. In animals, at 2 years, the lumen diameter of the reference vessel and polymer scaffold stabilized showing no step effect, (p<0.05) in contrast to metal. Follow-Up Lumen Area Follow-Up Reference Vessel Area Remodeling Ratio = Bioresorbable (No Drug) Bare Metal

Scaffold Resorbs and Vessel Achieves Tubularity 3 Mos 4.5 Yrs

What we think is happening... Post-Implant 1 Month 54 Months Bioresorbable (No Drug) Bare Metal

3-Year Follow-Up Bioresorbable Scaffold - - RESORB Trial Patient Case Baseline Angiography 80% Stenosis

3-Year Follow-Up of Bioresorbable Scaffolds - RESORB Trial Patient Case Scaffold Post-Implant Post-Implant Scaffold 4 Months 12 Months 28% NIH Volume by IVUS Post-Implant 12% NIH Volume by IVUS 15% NIH Volume by IVUS Scaffold Scaffold 34 Months

4 months 34 months 12-months Post-Implant 3-Year Follow-Up of Bioresorbable Scaffolds - RESORB Trial Patient Case

IVUS Lumen and Scaffold Area Changes with REVA 1st Generation Non-Drug Eluting Scaffold Lumen CSA %Neointimal Volume Post Implant 4 Months 1 Year 3 Year Post Implant 4 Months 1 Year 3 Year

Studies confirm that bioresorbable scaffolds: Universally undergo long-term, desirable geometric arterial changes Appear to re-establish vascular homeostasis and patency toward those characterizing a native artery Multimodality Imaging In vivo angiography, rotational angiography, IVUS and OCT provide additional insight in the evaluation of bioresorbable scaffolds Bioresorbable Scaffolds: Unique Long-term Outcomes

Second Generation Bioresorbable Scaffold ReZolve Stent Sirolimus-Eluting Bioresorbable Coronary Stent Drug-eluting (Sirolimus) Stronger and More Resilient Polymer Optimized Design

Future Clinical Plans RESTORE Pilot Study Start Q2-2011 50 patient pilot safety study Principal Investigator: Alexandre Abizaid Follow up at 1, 6 and 12 months and yearly thereafter No comparator